Sam Brusco, Associate Editor03.22.22
BD (Becton, Dickinson and Company) recently provided details about the planned spinoff of its Embecta Corp. (embecta) diabetes business. BD is expected to complete embecta’s spinoff on April 1.
The embecta name comes from the “em-” prefix to provoke empathy and empowerment for diabetes patients and the “bect” from Becton Dickinson. Upon completion, embecta will be one of the largest pure-play diabetes management companies in the world, leveraging a nearly 100-year legacy in insulin delivery.
BD set a record date of Mar 22 for embecta common stock share distribution. Embecta common stock began trading yesterday under the ticker “EMBCV.”
BD’s worldwide president of diabetes care Devdatt (Dev) Kurdikar will lead the company as CEO and will serve on embecta’s board of directors. Several other BD Diabetes executives will also continue their executive positions once the spinoff is complete.
"The Diabetes Care business is the trusted partner our customers and people living with diabetes have known for nearly a century, now with a single focus and the financial flexibility to pursue organic and inorganic innovations that will give more people a better life,” Kurdikar told the press when embecta’s board of directors was announced. “We have assembled a diverse and experienced leadership team that is excited about the possibilities ahead, and our global team is passionate about the profound impact they can have on the growing number of people who live with this chronic and prevalent disease. Together, we look forward to making embecta synonymous with a life unlimited by diabetes."
The embecta name comes from the “em-” prefix to provoke empathy and empowerment for diabetes patients and the “bect” from Becton Dickinson. Upon completion, embecta will be one of the largest pure-play diabetes management companies in the world, leveraging a nearly 100-year legacy in insulin delivery.
BD set a record date of Mar 22 for embecta common stock share distribution. Embecta common stock began trading yesterday under the ticker “EMBCV.”
BD’s worldwide president of diabetes care Devdatt (Dev) Kurdikar will lead the company as CEO and will serve on embecta’s board of directors. Several other BD Diabetes executives will also continue their executive positions once the spinoff is complete.
"The Diabetes Care business is the trusted partner our customers and people living with diabetes have known for nearly a century, now with a single focus and the financial flexibility to pursue organic and inorganic innovations that will give more people a better life,” Kurdikar told the press when embecta’s board of directors was announced. “We have assembled a diverse and experienced leadership team that is excited about the possibilities ahead, and our global team is passionate about the profound impact they can have on the growing number of people who live with this chronic and prevalent disease. Together, we look forward to making embecta synonymous with a life unlimited by diabetes."